Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow

Executive Summary

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."

Advertisement

Related Content

Sanofi Top UK Exec Plans For Hard Brexit, Blasts 'Poor Access' To New Drugs
Brexit Could Make UK A 'Second-Tier State' For Innovative New Drugs, Business Committee Warns
‘Do Not Rely On The Brexit Transition Period!’ EC Warns Hesitant Pharma Firms
What Pharma Firms Should Be Doing Now To Prepare For A ‘No Deal’ Brexit
No EMA Membership For UK After Brexit, Says European Council

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123107

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel